Document is current

Article History

Received: 22 October 2024

Accepted: 14 February 2025

First Online: 7 March 2025

Declarations

:

: P. Naval-Baudin, K. Pérez-Alfonso, A. Castillo-Pinar, I. Martínez-Zalacaín, P. Arroyo-Pereiro, L. Romero-Pinel, N. Calvo, M. Cos, A. Pons-Escoda and C. Majós declare that they have no competing interests. The institution where S. Martínez-Yélamos and A. Martinez-Yélamos work (Hospital Universitari de Bellvitge/Institut d’Investigació Biomèdica de Bellvitge) has received, in the last 3 years, fees exclusively to support the research of the Unit from advisory councils, collaborations, donations, and advice from Almirall, Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Horizon/Amgen, Janssen, Kern Pharma, Lilly, Merck, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. S. Martínez-Yélamos and A. Martinez-Yélamos have received support for attending congresses in the last 3 years from Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, and Sandoz.

: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Research Ethics Committee of Bellvitge University Hospital. Informed consent was waived due to the retrospective, non-interventional nature of the study and the confidentiality measures applied.